Vesugen
Not FDA approvedSynthetic short peptide bioregulator
Very thin human evidence
- Regulatory standing. Sold as a research chemical, not approved
- Animal / preclinical only. Evidence is largely animal or in-vitro
- No registered human trials. Nothing registered on ClinicalTrials.gov
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Vesugen is a synthetic tripeptide (commonly described as Lys-Glu-Asp) developed in Russia as part of the Khavinson peptide bioregulator research program. It is proposed to act on vascular tissue by influencing gene expression in blood vessel wall cells, though this mechanism has not been independently confirmed.
What the evidence shows
Evidence is limited to a small number of published papers, largely from a single research group and mostly in cell culture or animal models. There are no registered human clinical trials, and no benefit in humans has been established.
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Peptides tissue-specifically stimulate cell differentiation during their aging.
[Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging].
Peptidegic stimulation of differentiation of pineal immune cells.
[Biological activity of regulatory peptides in model experiments in vitro].
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.